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An underlying complex genetic susceptibility exists in multiple sclerosis (MS), and an association with the HLA-
DRB1*1501-DQB1*0602 haplotype has been repeatedly demonstrated in high-risk (northern European) popula-
tions. It is unknown whether the effect is explained by the HLA-DRB1 or the HLA-DQB1 gene within the sus-
ceptibility haplotype, which are in strong linkage disequilibrium (LD). African populations are characterized by
greater haplotypic diversity and distinct patterns of LD compared with northern Europeans. To better localize the
HLA gene responsible for MS susceptibility, case-control and family-based association studies were performed for
DRB1 and DQB1 loci in a large and well-characterized African American data set. A selective association with
HLA-DRB1*15 was revealed, indicating a primary role for the DRB1 locus in MS independent of DQB1*0602.
This ﬁnding is unlikely to be solely explained by admixture, since a substantial proportion of the susceptibility
chromosomes from African American patients with MS displayed haplotypes consistent with an African origin.
Evidence of disease risk heritability in multiple sclerosis
(MS [MIM 126200]) is supported by familial aggrega-
tion of cases (Ebers et al. 1995; Robertson et al. 1996;
Sadovnick et al. 1996, 2000) and by the high prevalence
in some ethnic populations (particularly those of north-
ern European origin) compared with others (African and
some Asian groups) irrespective of geographic location
(Compston 1998). Modeling of the available data pre-
dicts that the MS-prone genotype results from multiple
independent or interacting polymorphic genes, each ex-
erting a small—or, at most, a moderate—effect on the
overall risk. The HLA-DR2 haplotype (DRB1*1501-
DQB1*0602) within the major histocompatibility com-
plex on chromosome 6p21 has consistently demon-
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strated both linkage and association in family and
case-control studies (Multiple Sclerosis Genetics Group
1998). However, ﬁne-mapping studies have not settled
whether the effect is explained by the DRB1 gene itself
(MIM 142857); by another closely spaced gene within
the class II HLA region, such as DQB1 (MIM 604305);
or by some other nearby gene in strong disequilibrium
with the HLA-DR locus. Analyses have been made more
complex by extensive linkage disequilibrium (LD) oc-
curring across the region and by the presence of 1240
genes within this superlocus, many of which have roles
in immune function and are thus plausible disease can-
didates. Results suggesting that genes of interest for MS
exist within the class III (de Jong et al. 2002; Palacio et
al. 2002) and/or telomeric to the class I regions (Shinar
et al. 1998; Fogdell-Hahn et al. 2000; Marrosu et al.
2001; Rubio et al. 2002) have been reported as well.
Because patterns of LD differ between populations, the
most direct and practical approach to resolving this com-
plex genetic obstacle will be to scrutinize and compare
a large number of MS haplotypes in well-characterized
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data sets from distinct populations. However, studies of
HLA and MS in low-risk ethnic groups have generally
utilized small cohorts, and the results have been incon-
clusive or conﬂicting (Serjeantson et al. 1992; Kelly et
al. 1995; Caballero et al. 1999; Kwon et al. 1999; Quel-
vennec et al. 2003).
Compared with northern Europeans and white Amer-
icans, African Americans are at a lower risk for MS
(Kurtzke et al. 1979), but genetic studies of HLA and
other loci in this population can be extremely valuable
for disease gene identiﬁcation, because of the presence
of distinctive patterns of disequilibrium shaped by the
population history of the group (Just et al. 1997; Za-
chary et al. 1997). Some combinations in cis of DRB1
and DQB1 alleles are unique to African Americans, and,
more speciﬁcally, the DRB1*1501 and DQB1*0602 al-
leles do not display the high degree of LD and haplotype
ﬁxity in African Americans that is characteristic of
Europeans.
To localize the HLA gene responsible for MS suscep-
tibility, we performed case-control and family-based as-
sociation studies for DRB1 and DQB1 loci in a large
African American cohort consisting of 1,003 genotyped
individuals. The data set comprised 336 unrelated pa-
tients with MS (female:male ratio 4.6:1; mean age at
onset 32.79.4 years; mean disease duration 9.17.1
years), available nuclear family members ( ), andnp 357
unrelated control individuals ( , primarily pa-np 310
tient spouses). Families included 33 complete trios (both
parents and the affected individual), 162 families with
one parent, and 100 discordant sib pairs (one affected
and one unaffected individual). All study participants
were self-reported African Americans, but European an-
cestry in patients and controls was documented on the
basis of genotyping results of 186 SNPs. Based on the
use of two parent populations, West Africans and Euro-
peans, these SNPs have a mean 54% allele frequency
differences between the parental populations and are
spaced at least 10 cM from each other across the genome
(Parra et al. 1998). Global estimation of European an-
cestry in 50 patients and 50 controls indicated 19.1%
admixture in both groups (data not shown). Institutional
review board approval and informed consent were ob-
tained from all study participants. Medical records of
all patients were reviewed by one of the authors (S.L.H.
or B.A.C.C.) and, in all cases, diagnosis was conﬁrmed
using standard criteria (Poser et al. 1983). A total of
92% of patients had relapsing-remitting MS at onset.
Global testing for class II HLA-DRB1 and -DQB1 in
the African American patient-control data set revealed
differences in allele distributions ( and4Pp 4.0# 10
, respectively). Whereas the DQB1 effect wasPp .02
restricted to the DQB1*0602 allele only (odds ratio
[OR] 1.4; ), disease association at the DRB1Pp .01
locus was found for both DRB1*15 and DRB1*0301
alleles (OR 1.7, for DRB1*15; and OR4Pp 6.0# 10
1.7, for DRB1*0301; see table 1). As observedPp .01
in white MS data sets, there was an increased risk, albeit
not as pronounced, for the DRB1*1501 allele (OR 1.7;
) and the DRB1*1501-DQB1*0602 haplotypePp .03
(OR 1.6; ) in African Americans (table 1).Pp .049
In addition, associations were observed for both the
DRB1*1503 allele (OR 1.6; ) and the commonPp .015
African haplotype DRB1*1503-DQB1*0602 (OR 1.5;
). Two-locus DRB1-DQB1 haplotypes were de-Pp .02
duced on the basis of known associations (Fernandez-
Vina et al. 1991; Lin et al. 1997). As an additional mea-
sure of validation, DR-DQ haplotype frequencies in
patients and controls were also estimated from genotype
data via the method of maximum likelihood, through
the use of the expectation-maximization algorithm (Ar-
lequin version 2.0 [Arlequin’s Home on the Web]) under
the assumption of Hardy-Weinberg equilibrium (Excof-
ﬁer and Slatkin 1995; Long et al. 1995), and were con-
ﬁrmed, whenever possible, by available family data.
It is important that theDRB1*1501 and *1503 disease
associations were independent of DQB1*0602, as evi-
denced by the fact that chromosomes carrying the *0602
allele with other DRB1 alleles were present at identical
frequencies in patients and controls (4.0%; ).Pp .77
Conversely, DRB1*15 (including *1501 and *1503)
chromosomes carrying other DQB1 alleles (non-*0602
and denoted by “X”) were signiﬁcantly increased in pa-
tients with MS (OR 3.7; ; see table 1). PatientsPp .01
and controls were also grouped, by genotype, according
to whether they carried at least oneDRB1*15 and/or one
DQB1*0602 allele, to rule out the possibility of trans
allelic effects (table 2). In these analyses, for example, the
effect in an individual of DRB1*15 on one chromosome
in trans with DQB1*0602 on the other chromosome is
eliminated (see the DRB1*15/DQB1*0602 genotypic
category), and an independent role for DQB1*0602 un-
masked by DRB1*15 can be assessed. As shown in table
2, our results do not indicate the involvement of
DQB1*0602 in MS susceptibility. An increased risk in
individuals carrying the DRB1*15/DQB1*0602 ge-
notype was not observed (OR 1.0; ). Further-Pp .99
more, the analyses of DRB1*15/DQB1*0602 and
DRB1*15/DQB1*0602 haplotypes did not reveal ad-
ditional susceptibility alleles acting in an asymmetric fash-
ion. A diverse array ofDRB1 alleles, includingDRB1*03,
*08, *11, *13, *14 and *16, were present in similar
proportions on DRB1*15/DQB1*0602 haplotypes in
patients and controls (data not shown). DRB1*15/
DQB1*0602 haplotypes also displayed marked hetero-
geneity and includedDQB1*02, *03, *0501, *502, *601
*0603, *0609, *0615, and *0617 alleles distributed
equally in both groups. Nonetheless, much larger data
sets will be required to exclude the possibility of minor
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Table 1
HLA-DR2– and HLA-DR3–Related Alleles and Haplotypes in African American
Patients with MS and Controls
ALLELE OR HAPLOTYPE
NO. (%) OF
OR 95% CI P VALUE
Patients
( )2Np 672
Controls
( )2Np 620
Allelea:
DRB1*0301 72 (10.7) 42 (6.8) 1.7 1.1–2.5 .01
DRB1*15b 149 (22.2) 91 (14.7) 1.7 1.2–2.2 .0005
DRB1*1501 49 (7.3) 27 (4.4) 1.7 1.1–2.8 .03
DRB1*1503 100 (14.9) 64 (10.3) 1.5 1.1–2.1 .014
DQB1*0602 158 (23.5) 111 (17.9) 1.4 1.1–1.9 .01
DRB1-DQB1 haplotypec:
0301-0200d 72 (10.7) 41 (6.6) 1.7 1.1–2.5 .009
1501-0602 41 (6.1) 25 (4.0) 1.7 1.0–2.8 .049
1503-0602 90 (13.4) 61 (9.8) 1.5 1.1–2.1 .02
15-0602 131 (19.5) 86 (13.9) 1.5 1.1–2.1 .004
X-0602 27 (4.0) 25 (4.0) 1.1 .6–1.9 .74
15-X 18 (2.7) 5 (.8) 3.7 1.3–9.9 .007
1501-X 8 (1.2) 2 (.3) 4.1 .9–19.2 .06
1503-X 10 (1.5) 3 (.5) 3.4 .9–12.4 .05
NOTE.—Molecular typing of HLA-DRB1 and -DQB1 loci was performed using a
nonradioactive PCR-based sequence-speciﬁc oligonucleotide probe reverse line-blot assay
(Dynal). DRB1*15/DRB1*03/DQB1*06 subtyping was performed for all individuals,
through use of a similar approach, after allele-speciﬁc ampliﬁcation of the DR2 allele
(Bugawan et al. 2002). For other DRB1 and DQB1 alleles not distinguished by this
method, the resolution is reported at the lowest level common to any particular allele.
a Reference group: all other DRB1 or DQB1 alleles. P values (x2 or Fisher’s exact test,
when appropriate), ORs, and CIs were derived using PROC FREQ (SAS version 8.2).
b IncludesDRB1*1501 and *1503 alleles only.DRB1*1502was also present in patients
and controls but was very rare (.1% and .8%, respectively).
c The reference group for DRB1*0301-DQB1*0200 haplotype comparison was all
other haplotypes. To distinguish theHLA-DR2 related haplotype effect, all non-DRB1*15
and non-DQB1*0602 haplotypes were used as the reference group for DRB1*15- and
DQB1*0602-related haplotypes.
d Primarily DRB1*0301-DQB1*0201 haplotypes. Does not include DRB1*03021-
DQB1*0402 haplotypes.
heterogeneous multiallelic DRB1 and DQB1 interactions
inﬂuencing disease susceptibility in MS.
All DRB1*0301-associated chromosomes in African
American patients and controls carriedDQB1*02 alleles;
the vast majority were the common autoimmune disease-
associated haplotype DRB1*0301-DQB1*0201. The ef-
fect for the DRB1*0301 allele considered alone or in
combination with DQB1*02 was identical (OR 1.7;
), and no evidence for association in patientsPp .01
with non-DRB1*0301 haplotypes bearing DQB1*02
alleles (or X-DQB1*02) was observed (OR 0.8; Pp
; data not shown). These results further support an.14
independent role for DRB1*0301 in MS, rather than
variation at the DQB1 locus. The patient data set was
also compared with another large published African
American control group ( individuals) (Just etNp 242
al. 1997), with similar results (data not shown). Signif-
icant associations for DRB1*15 (OR 1.4; 95% CI 1.1–
1.9; ) and DRB1*0301 (OR 1.6; 95% CI 1.1–Pp .02
2.5; ) and no independent association withPp .03
DQB1*0602 (OR 1.0; 95% CI 0.8–1.3; ) orPp .94
X-*0602 haplotypes (OR 0.6; 95% CI 0.3–1.0;
) were observed. Further, the frequencies ofPp .04
predominantly African DRB1*03021-DQB1*0402
and DRB1*1304-DQB1*0301 and of northern Eu-
ropean DRB1*0800-DQB1*0402 haplotypes in pa-
tient and control groups were statistically indistin-
guishable (6.6%–5.2%, for DRB1*03021-Pp .57
DQB1*0402; 0.5%–1.2%, for DRB1*1304-Pp .28
DQB1*0301; and 0.5%–0.9%, for DRB1Pp .64
*0800-DQB1*0402). These observations, together with
the SNP genotyping results mentioned above, indicate
that the patients with MS and the controls used in this
study were adequately matched.
To further address the possibility that the case-control
results might be inﬂuenced by population stratiﬁcation,
family-based analyses of the HLA-DRB1 and DQB1 loci
were performed in a subgroup of patients for whom in-
formative family controls were available (table 3). Evi-
dence for excess transmission of the DRB1*1501 allele
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Table 2
DRB1*15 and DQB1*0602 Genotypes in African American Patients with MS and Controls
GENOTYPE
NO. (%) OF
ORa 95% CI P ValuePatients Controls HWb
DRB1*0602*15/DQB1*0602 123 (36.6) 76 (24.5) 86 (27.7) 1.6 1.1–2.2 .01
DRB1*15/DQB1*0602 11 (3.3) 4 (1.3) 4 (1.3) 3.0 .9–9.6 .05
DRB1*15/DQB1*0602 23 (6.8) 24 (7.7) 25 (8.1) 1.0 .5–1.9 .99
NOTE.—Patients and controls were grouped according to whether they carried at least one DRB1*15
and/or one DQB1*0602 allele. For example, the genotypic category DRB1*15/DQB1*0602 contains
individuals carrying at least one DRB1*15 and one DQB1*0602 allele, regardless of chromosomal phase,
and would include the following combination of genotypes: DRB1*15-DQB1*0602/DRB1*15-
DQB1*0602, DRB1*15-DQB1*0602/DRB1*15-X (where “X”p non-DQB1*0602 alleles),DRB1*15-
DQB1*0602/ X-DQB1*0602 (where “X” p non-DRB1*15 alleles), DRB1*15-DQB1*0602/X (where
“X” p all other non-DRB1*15–non-DQB1*0602 haplotypes), and DRB1*15/X-DQB1*0602 (where
“X”p non-DQB1*0602 alleles). Similarly, the DRB1*15/DQB1*0602 category comprised individuals
with DRB1*15-X/X genotypes (where “X” p non-DQB1*0602 alleles and “X” p all other non-
DRB1*15–non-DQB1*0602 haplotypes, respectively) and DRB1*15-X/DRB1*15-X genotypes (where
“X”p non-DQB1*0602 alleles). For these analyses, the Hardy-Weinberg expected genotype frequencies
for the control subjects were used, rather than the actual observed genotype counts, to obtain greater
precision in the OR estimates.
a The reference group for all OR estimates comprised X/X (DRB1*15/DQB1*0602) individuals.
b Number and percent expected under Hardy-Weinberg conditions.
Table 3
African American MS Family-Based Association Test
Results for HLA-DRB1 and HLA-DQB1
ALLELE
TRANSMISSION
PDT (All)a
PDT (Trios
Only)a TRANSMITb
DRB1 global .33 .73 .057
DRB1*1501 .04 .025 .0006
DRB1*1503 .70 .67 .56
DRB1*0301 .30 .56 .39
DQB1 global .47 .84 .34
DQB1*0602 .61 .53 .40
NOTE.—Two complementary approaches were used to
look for evidence of excess transmission of DRB1 and
DQB1 alleles in African American families. The PDT (Mar-
tin et al. 2000, 2001; Pedigree Disequilibrium Test Analysis
Program Web site) can utilize both discordant sib pairs and
nuclear families from extended pedigrees. TRANSMIT
(Clayton and Jones 1999) is restricted to parent-offspring
triads but can consider transmission of alleles or haplotypes
even in the presence of phase uncertainty and missing pa-
rental genotypes.
a PDT analysis utilized 33 trios and 100 discordant sib
pairs.
b TRANSMIT analysis utilized 162 families.
to affected individuals was observed when the pedigree
disequilibrium test (PDT) was used, for all families
( ) and for trios only ( ). TRANSMITPp .04 Pp .025
(available from David Clayton’s Web site) also yielded
signiﬁcant results for DRB1*1501 ( ). Associ-Pp .0006
ations with other DRB1 or DQB1 alleles were not ob-
served. Although only a fewDRB1*1501,DQB1*Xhap-
lotypes were identiﬁed in the family data set, TRANSMIT
results for this haplotypic classiﬁcation were also sup-
portive of an independent DRB1*1501 association, but
not for DQB1*0602 (data not shown). The failure to
detect evidence for statistically signiﬁcant excess trans-
mission of DRB1*1503 and DRB1*0301 alleles was
likely due to the small number of informative trios avail-
able for analysis.
In summary, we report a selective association with
DRB1*15, indicating a primary role for the DRB1 locus
in MS independent of DQB1. An approach similar to
that reported here was previously used to identify the
primary class II region gene associated with the sleep
disorder narcolepsy, another HLA-DR2-related disorder
(Mignot et al. 2001). In striking contrast to MS, the spe-
ciﬁc HLA association in African American narcolep-
tic patients was with DQB1*0602 rather than with
DRB1*1501. A primary role for DRB1*15 in suscepti-
bility to MS is consistent with a pathogenesis model that
involves a T cell–mediated autoimmune response against
the 85-99 peptide of myelin basic protein (MBP) (Alle-
gretta et al. 1990; Pette et al. 1990; Oksenberg et al.
1993; Krogsgaard et al. 2000). The crystal structure of
DRb*1501 differs from other non-DR2-relatedDRbmol-
ecules, in that aromatic residues in the ligand are preferred
in the large hydrophobic P4 pocket of the peptide-binding
domain (Smith et al. 1998). For MBP, this pocket is pri-
marily occupied by the aromatic side chain Phe92, acting
as an important primary anchor and accounting for its
high-afﬁnity binding to the HLA-DRa*0101/DRb*1501
heterodimer. Although structural features ofDRB1*1503
have not been described, the two DRB1*15 alleles differ
only at position 30 (Tyr in *1501, His in *1503) (ﬁg.
1A). Recent immunologic studies have demonstrated the
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Figure 1 Molecular structures of MS-prone HLA-DRb1 alleles.
A, HLA-DRb1*1501 and -DRb1*1503 allelic structure are superim-
posed using MINRMS, a program for ﬁnding minimal root mean
squared distance alignments between two proteins as a function of the
number of matching residue pairs within a heuristically limited search
space. The resulting structures were displayed as rods through use of
Chimera (UCSF Chimera Home Page), an interactive molecular graphics
program (Chiang et al. 2003). The structure of DRb*1503 was devel-
oped from the DRb*1501 crystal structure (Protein Data Bank [PDB]
ID 1BX2) by mutating the residue at position 30 from Tyr to His, using
the software Swiss PDB-viewer. The distinctive residues at position 30—
Tyr for *1501 and His for *1503—are shown in green and magenta,
respectively. Polymorphic residue Val b86 (critical for the hydrophobic
pocket characteristic of DR2 and DR3 alleles) is shown in green. MBP
peptide 85-99 and its electronic cloud are shown in gray. B, HLA-
DRb1*1501 (green) is superimposed on DRb1*0301 (PDB ID 1A6A;
red) in a top view, and their differences are highlighted in dark green
and yellow, respectively. Most of the allele-speciﬁc residues are in close
proximity to the peptide and thus likely affect the MBP binding afﬁnity.
Residue DRb1*0301Val 86 is shown in red. Residue labels are colored
according to that of their respective molecule. For clarity, the DRa chain
was omitted in these representations.
capability of DRB1*1503 to present the immunodomi-
nant autoantigen MBP 85-99 peptide to a DRB1*1501
restrictedMBP-speciﬁc T cell line (Quelvennec et al. 2003)
and suggest that *1501 and *1503 molecules may act
similarly in MS development.
The polymorphic residue at DRb position 71 is
also critically important in creating the necessary
space for Phe92 of MBP, and Ala at this position has
been observed only for DR15 alleles (DRB1*1501–
DRB1*1506) and for DRB1*1309 but not for
DRB1*0301. HLA-DRB1*1501, DRB1*1503, and
DRB1*0301 alleles, on the other hand, all share a crit-
ical Val residue at position 86, where the HLA-DRb
chain is also polymorphic, and can encode either Val or
Gly. DRbVal86 at the base of the P1 pocket results in
a smaller pocket than that observed for DR1 and DR4
(Gly), for example, inﬂuencing not only binding and
presentation of a number of self antigens, including
MBP, but also DRab dimer stability (Verreck et al. 1993;
Wucherpfennig et al. 1994; Smith et al. 1998). The
Val86/Val86 genotype has been implicated in association
studies in Swedish and Australian populations with MS
(Allen et al. 1994; Teutsch et al. 1999). The HLA-DR3
(DRB1*0301-DQB1*0201) association with MS de-
scribed here in African Americans has been demon-
strated elsewhere in Sardinian patients (Marrosu et al.
1998) and has been implied in otherMS studies of north-
ern European populations as well (Allen et al. 1994).
The high-risk HLA-DR2 (DRB1*1501-DQB1*0602)
association can also be detected in Sardinian data sets
(Marrosu et al. 2001), along with other DRB1-DQB1
haplotypes, emphasizing the complex multiallelic nature
of class II involvement in MS. Current understanding of
the molecular structure of DRB1*15 alleles, illustrated
in the simulated structure comparison shown in ﬁgure
1A, also proposes that both *1501 and *1503 have sim-
ilar functional roles in MS susceptibility. The molecular
structures of DRB1*1501/*1503 and DRB1*0301 are
signiﬁcantly divergent in the proximity of the bound
peptide, suggesting that they present either a different
MBP epitope or a different antigen (ﬁg. 1B).
The 7.3% frequency of the DRB1*1501 allele ob-
served in this African American cohort with MS is low
compared with the expected frequency of ∼50% inwhite
American populations with MS. On the other hand, it
is substantially higher than published frequencies in
most control African populations. Genetic admixture is
one possible source of DRB1*1501 alleles in African
American patients with MS, and some degree of ad-
mixture probably accounts for some of the observed
DRB1*1501-DQB1*0602 haplotypes in African Amer-
ican patients. However, admixture cannot fully account
for this observation, since 16% (8/49) of DRB1*1501
and 12% (18/149) of DRB1*15- (*1501- or *1503-)
bearing chromosomes in African Americans were not as-
Reports 165
sociated with DQB1*0602 alleles in cis. The haplotypic
features of these DRB1*1501-positive chromosomes in-
dicate an older African origin, predating the divergence
of human ethnic groups, rather than genetic admixture
with people of European descent. Positive selection for
DRB1*1501 appears to have occurred in Europeans but
not in Africans, and, although the factors that drove this
selection (presumably some infectious pathogen) are un-
known, one possible consequence was a heightened sus-
ceptibility to MS, a disorder almost nonexistent in Afri-
ca (Elian and Dean 1987; Modi et al. 2001). Since
DRB1*1501 and DRB1*1503 are both present in native
Africa, the low prevalence of MS in Africa is likely due
to additional protective genetic and/or environmental fac-
tors (Todd 1991; Zinkernagel 2001).
The current data underscore the power of ethnically
deﬁned cohorts to identify disease genes by association
for complex diseases. Here, we have provided strong
evidence for the direct involvement of the HLA-DRB1
gene in MS, as well as the presence of allelic heteroge-
neity. Taken together, our results indicate that variation
at the DQB1 locus does not play a primary role in dis-
ease susceptibility, though a modulating inﬂuence on
clinical outcome cannot be excluded and warrants fur-
ther investigation. It is likely that HLA-DRB1 consti-
tutes the centromeric boundary of the class II DR-DQ
association in MS, but this will need to be conﬁrmed by
additional centromeric genotyping, including analysis of
HLA-DP. In addition to the potential of this approach
for the localization of candidate genes, SNP markers
whose frequency differs between Africans and whites/
Asians could also be used in a whole-genome strategy
to search for new susceptibility or modiﬁer loci (Lau-
tenberg et al. 2000). As the MS genomic map in
Northern Europeans is increasingly reﬁned, well-char-
acterized African American MS data sets should prove
to be an extraordinarily valuable resource.
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wwwchg.mc.duke.edu/software/pdt.html
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